However, it cannot be ruled out that those effects could derive from the whole-body extensive metabolic changes induced by the treatment with SGLT2 inhibitors in conditions of obesity and diabetes. This evidence concerns the gene SLC5A2 and obesity due to melanocortin 4 receptor deficiency.